Company / R&D Expense
Enovis R&D Expense History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$120.3M
FY2025
5-year range
$34.3M / $120.3M
FY2021-FY2025
Trend
+31.8%
vs FY2024
Sector context
#50 of 110
Health Care
What the data says
At $120M, Enovis's r&d expense ranks #50 of 110 in the Health Care sector. R&D Expense has increased for 3 consecutive years, from $34M in FY2022 to $120M in FY2025.
Based on SEC 10-K filings.
$120M in FY2025 with a 3-year CAGR of +52.0%.
Improved from $49M to $120M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +52.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#50 of 110 in Health CareTop 45% of 110This company $120.3M Sector average $298.2M
▼
-59.6% below sector average
Key checks
Key Insights
- Enovis's r&d expense has grown for 3 consecutive years.
- 3-year CAGR of +52.0%, indicating consistent growth.
- In FY2025, r&d expense increased 31.8% year-over-year.
- Ranks #50 out of 110 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.27 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $120.3M | +31.8% |
| FY2024 | $91.3M | +86.0% |
| FY2023 | $49.1M | +43.3% |
| FY2022 | $34.3M | -30.2% |
| FY2021 | $49.1M | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026